Gyre Therapeutics, Inc. (GYRE)
(Delayed Data from NSDQ)
$11.36 USD
+0.95 (9.13%)
Updated May 31, 2024 04:00 PM ET
After-Market: $11.37 +0.01 (0.09%) 7:58 PM ET
3-Hold of 5 3
D Value A Growth B Momentum B VGM
Fundamental Charts
About Cash from Investing (TTM)
The company's trailing twelve month (TTM) Cash from Investing is the sum of the company's past 12 months cash position resulting from any gains or losses from investments in the financial markets, operating activities, and changes resulting from amounts spent on investments in capital assets such as plant and equipment. When evaluating the Cash from Investing value, it is important to consider each of the various activities which contribute to the overall change in cash position. A company can have a negative cash flow from investing and have a positive cash from Cash from operations or financing.
GYRE 11.36 +0.95(9.13%)
Will GYRE be a Portfolio Killer in June?
Zacks Investment Research is releasing its prediction for GYRE based on the 1-3 month trading system that more than doubles the S&P 500.
Other News for GYRE
Gyre Pharmaceuticals Receives IND Approval from China’s NMPA to Evaluate F230 for the Treatment of Pulmonary Arterial Hypertension
Gyre Therapeutics Advances with F230 IND Approval in China
Gyre Therapeutics files to sell 1.08M shares of common stock for holders
Gyre Therapeutics gets IND okay from China's NMPA to evaluate F230 for PAH
Gyre Therapeutics files $150M mixed securities shelf